HCTZ_SPE2D2-17-D-0060 I P00004 SIGNED.pdf
PDF 885 KB Posted
- Attached to
- Exercise of Option Year SPE2D217D0060P00006
- Solicitation number
- SPE2D217D0060
View the file
Other files
| File | Type | Posted |
|---|---|---|
| SPE2D2-17-D-0060 P00006 Option YR 3 Mod.pdf | ||
| SPE2D217D0060P00003_Option_Yr_2.pdf | ||
| SPE2D217D0060_P00002_OPTION_YEAR_1.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED:
SPE2D2-17-D-0060 I P00004
1. NDCs for all items on the contract are changed as follows effective July 1, 2020:
LINE ITEM FROM: TO:
0001 60429-0889-90 51407-0331-90
0002 60429-0889-01 51407-0331-01
0003 60429-0889-10 51407-0331-10
00004 60429-0890-90 51407-0332-90
0005 60429-0890-01 51407-0332-01
0006 60429-0890-10 51407-0332-10
0007 60429-0888-01 51407-0330-01
2. Manufacturer is changed effective July 1, 2020:
FROM
Teva Czech Industries, S.R.O.
Ostravska 29/305 Opava-Komarov, 74770 Czech, Republic Mark Blitman (813)792-9830 mark.blitman@actavis.com
TO:
Leading Pharma, 3 Oaks Rd.
Fairfield, NJ 07004 Douglas D. Statler
(480) 2681274 dstatler@leadingpharma.com
3. Packaging and Packing location remains the same.
PAGE 2 OF 2 PAGES
4. Revised FAR clause 52.215-6 Place of Performance is incorporated into the contract effective July 1, 2020. See attachment.
All other terms and conditions remain the same.
| 2020-06-23T15:10:59-0400 | |
| WRAY.JASON.CHRISTOPHER.1238740742 |
File details come from the government source that posted it. Updated .